Ivermectin

Generic Name
Ivermectin
Brand Names
Sklice, Soolantra, Stromectol
Drug Type
Small Molecule
Chemical Formula
C95H146O28
CAS Number
70288-86-7
Unique Ingredient Identifier
8883YP2R6D
Background

Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of Streptomyces avermitilis. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A (22,23-dihydroavermectin B) and 10%...

Indication

Administered topically, ivermectin cream is indicated for the treatment of inflammatory lesions associated with rosacea. An over-the-counter ivermection lotion is commercially available and indicated for the topical treatment of head lice infestations in patients ≥6 months of age.
...

Associated Conditions
Ascariasis, Demodex Infestation, Enterobiasis, Filariasis caused by Loa Loa, Gnathostomiasis, Head Lice Infestation, Malaria, Myiasis, Onchocerciasis caused by Infection with Onchocerca volvulus, Rosacea, Scabies, Strongyloidiasis caused by Strongyloides Stercoralis Infection, Trichuriasis
Associated Therapies
-
Clinical Trials
Related News

Ivermectin for Severe COVID-19 Management

Phase 3
Completed
Conditions
COVID-19
Interventions
Drug: Ivermectin
First Posted Date
2020-11-27
Last Posted Date
2021-01-27
Lead Sponsor
Afyonkarahisar Health Sciences University
Target Recruit Count
66
Registration Number
NCT04646109
Locations
🇹🇷

Afyonkarahisar Health Science University, Afyonkarahisar, Turkey

🇹🇷

Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey

🇹🇷

Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey

and more 1 locations

Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19

First Posted Date
2020-11-19
Last Posted Date
2021-12-06
Lead Sponsor
Universidad Peruana Cayetano Heredia
Target Recruit Count
186
Registration Number
NCT04635943
Locations
🇵🇪

Hospital Nacional Cayetano Heredia, Lima, Peru

Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19

Phase 1
Completed
Conditions
Covid19
Interventions
Drug: Placebo
Drug: Ivermectin
First Posted Date
2020-11-17
Last Posted Date
2021-12-27
Lead Sponsor
MedinCell S.A
Target Recruit Count
24
Registration Number
NCT04632706
Locations
🇬🇧

MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence, Manchester, Greater Mancherster, United Kingdom

Ivermectin in Adults With Severe COVID-19.

First Posted Date
2020-10-26
Last Posted Date
2022-01-04
Lead Sponsor
CES University
Target Recruit Count
75
Registration Number
NCT04602507
Locations
🇨🇴

Clinica CES, Medellín, Antioquia, Colombia

Ivermectin to Prevent Hospitalizations in COVID-19

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Placebo
Drug: Ivermectin
First Posted Date
2020-08-27
Last Posted Date
2021-07-07
Lead Sponsor
Instituto de Cardiología de Corrientes
Target Recruit Count
501
Registration Number
NCT04529525
Locations
🇦🇷

Ministry of Public Health of the Province of Corrientes, Corrientes, Argentina

Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel

First Posted Date
2020-08-26
Last Posted Date
2020-08-26
Lead Sponsor
Javeriana University
Target Recruit Count
550
Registration Number
NCT04527211
Locations
🇨🇴

Pontificia Universidad Javeriana, Cali, Valle Del Cauca, Colombia

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

First Posted Date
2020-08-12
Last Posted Date
2024-05-16
Lead Sponsor
University of Minnesota
Target Recruit Count
1323
Registration Number
NCT04510194
Locations
🇺🇸

Hennepin County Medical Center, Minneapolis, Minnesota, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Olive View UCLA Medical Center, Sylmar, California, United States

and more 4 locations

Trial of Combination Therapy to Treat COVID-19 Infection

First Posted Date
2020-07-22
Last Posted Date
2021-11-02
Lead Sponsor
ProgenaBiome
Target Recruit Count
31
Registration Number
NCT04482686
Locations
🇺🇸

ProgenaBiome, Ventura, California, United States

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

First Posted Date
2020-07-07
Last Posted Date
2020-07-07
Lead Sponsor
Qassim University
Target Recruit Count
200
Registration Number
NCT04460547

Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

First Posted Date
2020-06-25
Last Posted Date
2022-08-09
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Target Recruit Count
77
Registration Number
NCT04447235
Locations
🇧🇷

Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy